Cargando…

Amino Acid Conjugates of 2-Mercaptobenzimidazole Ameliorates High-Fat Diet-Induced Hyperlipidemia in Rats via Attenuation of HMGCR, APOB, and PCSK9

[Image: see text] Purpose: This study was designed to explore the antihyperlipidemic effects of amino acid derivatives of 2-mercaptobenzimidazole (4J and 4K) in high-fat diet (HFD)-fed rats. Methods: Male Sprague-Dawley rats were divided into nine groups which received either standard diet or HFD fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shabbir, Ramla, Hayat Malik, Muhammad Nasir, Zaib, Maryam, Alamgeer, Jahan, Shah, Khan, Muhammad Tariq
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647896/ https://www.ncbi.nlm.nih.gov/pubmed/36385864 http://dx.doi.org/10.1021/acsomega.2c05735

Ejemplares similares

Imine Derivatives of Benzoxazole Attenuate High-Fat Diet-Induced Hyperlipidemia by Modulation of Lipid-Regulating Genes
por: Zaib, Maryam, et al.
Publicado: (2023)

Rewiring Lipid Metabolism by Targeting PCSK9 and HMGCR to Treat Liver Cancer
por: Alannan, Malak, et al.
Publicado: (2022)

Association between polymorphisms in the APOB gene and hyperlipidemia in the Chinese Yugur population
por: Gu, Q-L., et al.
Publicado: (2017)

Genetic variations in HMGCR and PCSK9 and kidney function: a Mendelian randomization study
por: Park, Sehoon, et al.
Publicado: (2023)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
por: Blom, Dirk J, et al.
Publicado: (2016)

2-Mercaptobenzimidazole clubbed hydrazone for Alzheimer’s therapy: In vitro, kinetic, in silico, and in vivo potentials
por: Begum, Farida, et al.
Publicado: (2022)

Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2020)

Pulegone Prevents Hypertension through Activation of Muscarinic Receptors and Cyclooxygenase Pathway in L-NAME-Induced Hypertensive Rats
por: Razzaq, Muryam Abdul, et al.
Publicado: (2023)

Atorvastatin Ester Regulates Lipid Metabolism in Hyperlipidemia Rats via the PPAR-signaling Pathway and HMGCR Expression in the Liver
por: Hu, Nan, et al.
Publicado: (2021)

Cerebrovascular Changes and Neurodegeneration Related to Hyperlipidemia: Characteristics of the Human ApoB-100 Transgenic Mice
por: Tóth, Melinda E., et al.
Publicado: (2020)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations
por: Futema, Marta, et al.
Publicado: (2014)

A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
por: Safarova, Maya S., et al.
Publicado: (2019)

Correction: Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations
por: Hayat, Mahtaab, et al.
Publicado: (2021)

Geraniol Suppresses Oxidative Stress, Inflammation, and Interstitial Collagenase to Protect against Inflammatory Arthritis
por: Malik, Muhammad Nasir Hayat, et al.
Publicado: (2023)

Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries
por: Rosoff, Daniel B., et al.
Publicado: (2023)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

Molecular Interaction Mechanism between 2-Mercaptobenzimidazole and Copper-Zinc Superoxide Dismutase
por: Teng, Yue, et al.
Publicado: (2014)

Anti-HMGCR Myopathy
por: Mohassel, Payam, et al.
Publicado: (2018)

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
por: Benn, Marianne, et al.
Publicado: (2017)

Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomisation study
Publicado: (2017)

Genetic Polymorphisms in LDLR, APOB, PCSK9 and Other Lipid Related Genes Associated with Familial Hypercholesterolemia in Malaysia
por: Lye, Say-Hean, et al.
Publicado: (2013)

The elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels
por: Drouin-Chartier, Jean-Philippe, et al.
Publicado: (2017)

Susceptibility of ApoB and PCSK9 Genetic Polymorphisms to Diabetic Kidney Disease Among Chinese Diabetic Patients
por: Ma, Liang, et al.
Publicado: (2021)

Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2
por: Pott, Janne, et al.
Publicado: (2021)

Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels
por: Lee, Chan Joo, et al.
Publicado: (2017)

Synthesis of Surfactants Derived from 2-Mercaptobenzimidazole and Study of Their Acute Toxicity and Analgesic and Psychotropic Activities
por: Nguema Ongone, Terence, et al.
Publicado: (2019)

Neuroprotective Properties of Quinone Reductase 2 Inhibitor M-11, a 2-Mercaptobenzimidazole Derivative
por: Voronin, Mikhail V., et al.
Publicado: (2021)

2-Mercaptobenzimidazole Functionalized Copper Nanoparticles Fluorescence Probe for Sensitivity and Selectivity Detection of Cys in Serum
por: Liu, Jing, et al.
Publicado: (2023)

Ameliorative Effects of Herbal Combinations in Hyperlipidemia
por: Visavadiya, Nishant P., et al.
Publicado: (2011)

Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
por: Ma, Shizhan, et al.
Publicado: (2019)

Anti-HMGCR antibodies in systemic sclerosis
por: Hudson, Marie, et al.
Publicado: (2016)

Synthesis of (99m)Tc-labeled 2-Mercaptobenzimidazole as a novel radiotracer to diagnose tumor hypoxia
por: Rizvi, Syed Faheem Askari, et al.
Publicado: (2020)

Adsorption efficacy of functionalized Cu-BDC MOFs tethered 2-mercaptobenzimidazole analogue: A comparative study
por: Challa, Malathi, et al.
Publicado: (2023)

A Critical Role of PCSK9 in Mediating IL-17-Producing T Cell Responses in Hyperlipidemia
por: Kim, Young Uk, et al.
Publicado: (2019)

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
por: Waldmann, Elisa, et al.
Publicado: (2022)

Syntheses, crystal structures and Hirshfeld surface analyses of bis(2-mercaptobenzimidazole)bromo- and iodocopper(I) complexes
por: Chooto, Pipat, et al.
Publicado: (2022)

Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis
por: Wu, Yue, et al.
Publicado: (2019)

Hyperlipidemia-induced apoptosis of hippocampal neurons in apoE(−/−) mice may be associated with increased PCSK9 expression
por: Zhao, Xue-Shan, et al.
Publicado: (2017)

CES1‐Triggered Liver‐Specific Cargo Release of CRISPR/Cas9 Elements by Cationic Triadic Copolymeric Nanoparticles Targeting Gene Editing of PCSK9 for Hyperlipidemia Amelioration
por: Zhao, Yunfei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6rgkvsqh1kika1cciu35vqf4l1